Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
| Image |  |
|---|---|
| Description | article |
| Author/s |
author: Mario Tiribelli Ahmet Emre Eskazan |
| Publication date | September 29, 2018 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |